ReviewFrontiers in physiology2022
Lupus nephritis: The regulatory interplay between epigenetic and MicroRNAs.
Review in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Epigenetic Modulation by Luteolin, Quercetin and Apigenin in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Enhanced WWP2 Exacerbates Podocyte Injury in Lupus Nephritis through Monoubiquitylating H2A at K119.International journal of biological sciences · 2026Article
- Identification of serum exosomal miRNA biomarkers in patients with lupus nephritis.Clinical rheumatology · 2025Article
- New Insights on Childhood Lupus Nephritis.International journal of nephrology and renovascular disease · 2025Review
- Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.Clinical and experimental medicine · 2024Review
- Lupus Nephritis from Pathogenesis to New Therapies: An Update.International journal of molecular sciences · 2024Review
- Special Issue "Epigenetics in Neurodegenerative Diseases".International journal of molecular sciences · 2024Article
- Circulatory microRNAs and proinflammatory cytokines as predictors of lupus nephritis.Frontiers in immunology · 2024Article
- Comparison of miRNA transcriptome of exosomes in three categories of somatic cells with derived iPSCs.Scientific data · 2023Article
- Application of herbal traditional Chinese medicine in the treatment of lupus nephritis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are endogenous, small, non-coding RNA molecules that act as epigenetic modifiers to regulate the protein levels of target messenger RNAs without altering their genetic sequences. The highly complex role of miRNAs in the epigenetics of lupus nephritis (LN) is increasingly being recognized. DNA methylation and histone modifications are focal points of epigenetic research. miRNAs play a critical role in renal development and physiology, and dysregulation may result in abnormal renal cell proliferation, inflammation, and fibrosis of the kidneys in LN. However, epigenetic and miRNA-mediated regulation are not mutually exclusive. Further research has established a link between miRNA expression and epigenetic regulation in various disorders, including LN. This review summarizes the most recent evidence regarding the interaction between miRNAs and epigenetics in LN and highlights potential therapeutic and diagnostic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.